Condition
Familial Hypercholesterolemia
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
5 shownPediatric Reporting of Adult-Onset Genomic ResultsNCT03832985 · 2020-11-25
COMPLETEDAn Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High CholesterolNCT03060577 · 2017-04-27
COMPLETEDPediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, GermanyNCT02750527 · 2016-09-01
COMPLETEDTrial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)NCT02597127 · 2016-01-01
COMPLETEDAmlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)NCT01107743 · 2010-06-01
COMPLETEDCommon interventions
Adolescent controls - negative for familial variantGENETIC1Adolescents who received a pediatric-onset resultGENETIC1Adolescents who received adult-onset resultGENETIC1ALN-PCSSCDRUG1Amlodipine/AtorvastatinDRUG1Child(ren) receive an adult-onset resultGENETIC1Child(ren) received a pediatric-onset resultGENETIC1Control - Negative ResultGENETIC1EvolocumabDRUG1InclisiranDRUG1Normal SalineDRUG1
Leading sponsors
Trial status mix
COMPLETED5
Phase mix
PHASE22
EARLY_PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.